A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Relapsed/Refractory Diffuse Large B-cell Lymphoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.3
6 insiders sold shares within a month
Since May 14, 2026 · was worth 10, fading over time
Score over time
- Stage
- Phase 2/3
- Patients
- 501 (planned)
- Started
- Sep 3, 2020
- Main results expected
- Dec 2026
- Fully finished
- Dec 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 2: Overall Response Rate (ORR): Based on Lugano Criteria 2014
Measured over: From date of initial randomization to the date of disease progression or initiating a new DLBCL treatment (maximum of 5 years from randomization)
Phase 3: Progression-free Survival (PFS): Based on Lugano Criteria 2014
Measured over: From date of initial randomization to the date of disease progression or death (maximum of 5 years from randomization)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.3, since 2026-05-14, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04442022 · record last updated 2026-10-02 · checked 2026-11-09 15:47 UTC